Fig 1.
Flow chart describing the study-populations.
Table 1.
Baseline characteristics of the study participants in the MDC-CC-re-examination-replication-cohort by prevalence of the metabolic syndrome.
Table 2.
Cystatin C and risk of future metabolic syndrome in the MDC-CC-re-examination-replication-cohort.
Table 3.
Cystatin C and rs13038305 and incidence of the individual components of the metabolic syndrome in the MDC-CC-re-examination-replication-cohort.
Table 4.
Cystatin C and risk of future metabolic syndrome in the MDC-CC-re-examination-cohort.